|
|
|
| Effects of Microecologics combined with Antiviral Therapy on Immune Function and Liver Fibrosis Indexes in Patients with Hepatitis B Cirrhosis |
| DUAN Hongyan |
| Panjin Liaohe Oilfield Gem Flower Hospital, Liaoning Panjin 124010, China |
|
|
|
|
Abstract Objective: To explore the effects of microecologics combined with antiviral therapy on immune function and liver fibrosis indexes in patients with hepatitis B cirrhosis. Methods: 84 patients with hepatitis B cirrhosis admitted to our hospital were randomly divided into control group and combined group, with 42 cases in each group. Control group was given antiviral drugs, and combined group was given microecologics combined with antiviral therapy. The HBV-DNA level, liver function, liver fibrosis indexes, immune function and inflammatory factors levels were compared between the two groups. Results: After treatment, the levels of hepatitis B virus nucleic acid (HBV-DNA) in the two groups were significantly decreased (P<0.05), and the difference of HBV-DNA level before and after treatment in combined group was significantly greater than that in control group (P<0.05), and there was no statistically significant difference in the negative conversion rate of HBV-DNA between the two groups (P<0.05). The levels of liver function indexes [aspartate aminotransferase (AST), alanine aminotransferase (ALT) and total bilirubin (TBIL)] were significantly decreased in the two groups (P<0.05), and the differences of liver function indexes before and after treatment in combined group were significantly greater than those in control group (P<0.05). The levels of liver fibrosis indexes [serum hyaluronic acid (HA), laminin (LN), type III procollagen N-terminal peptide (PIIIP) and type IV collagen (IV-C)] were significantly decreased in the two groups (P<0.05), and the differences of liver fibrosis indexes before and after treatment in combined group were significantly greater than those in control group (P<0.05). The levels of immune function indexes of T cell subsets (CD3+, CD4+ and CD4+/CD8+) in the two groups were significantly increased (P<0.05) while the CD8+ level was significantly decreased (P<0.05), and the differences of immune function indexes before and after treatment in combined group were significantly greater than those in control group (P<0.05). The levels of inflammatory factors [interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), high-sensitive C-reactive protein (hs-CRP)] were significantly decreased in the two groups (P<0.05), and the differences of inflammatory factors before and after treatment in combined group were significantly greater than those in control group (P<0.05). Conclusion: Microecologics combined with antiviral therapy has significant effects in improving liver function and immune function and reducing liver fibrosis and inflammatory factors in patients with hepatitis B cirrhosis, and it can improve the efficacy.
|
|
|
|
|
|
[1] Luvisa B K,Hassanein TI.Hepatitis B Virus Infection and Liver Decompensation[J].Clinics in Liver Disease,2016,20(4):681~692.
[2] 刘汶,冯金帅,龚然,等.肝硬化患者生存质量与中医证候积分、辨证分型的关系[J].北京中医药,2016,35(4):363~366.
[3] Kyeong Woo N,Young Hoon K,Duck Jong H,et al.Kidney transplantation alone in end-stage renal disease patients with hepatitis B liver cirrhosis:a single-center experience[J].Transplantation,2015,99(1):133~138.
[4] 谢晓,陆伦根.乙型肝炎肝硬化抗病毒治疗的进展[J].实用肝脏病杂志,2018,21(1):140~144.
[5] 陈娟娟,张瑞,陈保站,等.恩替卡韦治疗对乙肝肝硬化患者肝功能及肝硬化指标的影响[J].中国医院药学杂志,2018,38(14):1526~1529,1557.
[6] Siegel R,Ma J,Zou Z,et a.Cancer statistics[J].CA Cancer Clin,2014,64(1):9~29.
[7] 中华医学会肝病学分会中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].中国病毒病杂志,2015,31(12):1941,1960.
[8] 赵云,朱培福.恩替卡韦联合微生态制剂对乙肝肝硬化患者肝功能、HBV-DNA和肝纤维化指标的影响[J].河北医药,2018,40(5):759~761.
[9] Peng C Y,Chien R N,Liaw Y F.Hepatitis B virus-related decompensated liver cirrhosis:Benefits of antiviral therapy[J].Journal of Hepatology,2012,57(2):442~450.
[10] 林小萍,侯卫平,陆军平,等.恩替卡韦联合微生态制剂对乙肝肝硬化患者肝功能及预后的临床研究[J].实用医学杂志,2016,32(6):993~995. |
|
|
|
2019, Vol. 25 
